The economic value of targeting aging
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Abstract
Developments in life expectancy and the growing emphasis on biological and ‘healthy’ aging raise a number of important questions for health scientists and economists alike. Is it preferable to make lives healthier by compressing morbidity, or longer by extending life? What are the gains from targeting aging itself compared to efforts to eradicate specific diseases? Here we analyze existing data to evaluate the economic value of increases in life expectancy, improvements in health and treatments that target aging. We show that a compression of morbidity that improves health is more valuable than further increases in life expectancy, and that targeting aging offers potentially larger economic gains than eradicating individual diseases. We show that a slowdown in aging that increases life expectancy by 1 year is worth US$38 trillion, and by 10 years, US$367 trillion. Ultimately, the more progress that is made in improving how we age, the greater the value of further improvements.
Overview
CoChat Summary
TL;DR
Using a value-of-statistical-life economic model calibrated to US data, the paper finds that health-improving compression of morbidity is more valuable than further life extension, and that targeting aging itself yields larger economic gains than eradicating individual diseases. A slowdown in aging that adds 1 year of life expectancy is worth US$37.6 trillion, and one adding 10 years is worth US$366.8 trillion.
Key findings
- The willingness to pay for an extra year of healthy life expectancy always exceeds that for an extra year of life expectancy; individuals prefer compression of morbidity over further life extension.
- A 2017 slowdown in aging producing a 1-year increase in life expectancy is worth US$37.6 trillion total (US$29.7 trillion for those alive in 2017 and US$7.9 trillion for unborn generations); a 10-year increase is worth US$366.8 trillion (US$291.9 trillion and US$74.8 trillion, respectively). At a 2% interest rate, the 10-year gain is US$7.2 trillion annually, or 33.6% of 2019 GDP.
- Metformin, used as an example of targeting aging, often matches or exceeds the value of eradicating cancer, dementia, or cardiovascular diseases; treatment starting at age 75 raises life expectancy at birth by 2.9 years and at age 80 by 4.3 years, with healthy life expectancy gains of 1.7–2.5 years.
- Targeting aging creates a virtuous circle: the more society improves how it ages, the greater the aggregate economic value of further improvements, because gains rise with the average age of society and the number of older people.
Methods
- The authors use an economic model based on Murphy and Topel, calibrated to current US data, in which optimizing individuals choose consumption, hours worked, and leisure; willingness to pay is measured via value of statistical life, incorporating both quantity and quality of remaining life.
- Demographic inputs include a Gompertz survival function, a health deficit function, and 2017 US Census population structure and birth rates; baseline life expectancy at birth is 78.9 years and healthy life expectancy is 68.5 years, with adult VSL set at US$11.5 million for ages 25–65.
- Simulations cover life extension (Struldbrugg), compression of morbidity (Dorian Gray), slowing aging (Peter Pan), reversing aging (Wolverine), and metformin effects based on a study of 41,204 men with diabetes; aggregate WTP sums age-specific values using census data.
Limitations
- The paper states that metformin’s efficacy awaits confirmation from large trials such as TAME; the metformin estimates rely on a study of 41,204 men over 65 with diabetes, so factors may not accurately capture effects for women, non-diabetics, or those under 65, and metformin may have less impact at higher ages.
- The paper states that estimates abstract from inequalities in health and income; allowing for health inequalities likely increases aggregate gains, while income inequality raises distributional issues, and dollar WTP values are sensitive to model calibration though relative treatment rankings are not.
- Evident from the text: results are simulation-based rather than direct empirical estimates, depend on VSL and utility assumptions, and the Wolverine scenario requires additional auxiliary assumptions; aggregate projections also assume zero net immigration and current birth and mortality rates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
6 Valid · 1 Not valid · 9 Not checked · 52 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“These calculations abstract from the diversity of health across the US population32,33, so they are likely to underestimate the aggregate gains from delaying aging.”
§ The economic value of targeting aging > Results > Aggregate gains
What the sources say
- Supportedcites [32] Cantu, P. A., Hayward, M. D., Hummer, R. A. & Chiu, C.-T. New estimates of racial/ethnic differences in life expectancy with chronic morbidity and functional loss: evidence from the National Health Interview Survey. J. Cross Cult. Geront. 28, 283–297 (2013). source
The citation follows the statement that aggregate calculations abstract from health diversity across the US population. The Data, Measures, and Approach section reports substantial differences in life expectancy and lifetime health across racial/ethnic groups and between men and women, supporting that point. The subsequent inference about gains from delaying aging is the citing authors’ own conclusion, not a finding attributed to this source. (LLM, conf=0.89)
- Supportedcites [33] Garcia, M. A. et al. Educational benefits and cognitive health life expectancies: racial/ethnic, nativity, and gender disparities. Gerontologist 61, 330–340 (2020). source
The Discussion reports differences in cognitive health life expectancy by race/ethnicity, nativity, and gender, supporting the cited point that health varies across the US population. The claim that aggregate gains are likely underestimated follows the citation and is the citing authors’ inference, not a finding attributed to this paper. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent advances have shown that such regeneration is possible in mice and humans25,26.”
§ The economic value of targeting aging > Results > Reversing aging (the Wolverine case)
What the sources say
- Supportedcites [25] Fahy, G. M. et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell 18, e13028 (2019). source
This source supports the human part of the sentence: the Discussion reports highly significant evidence of thymic regeneration in normal aging men, and the Results report improved thymic MRI measures in 7 of 9 volunteers. The sentence has two citations; this human study need not establish the separate claim about mice. (LLM, conf=0.91)
- Partly supportedcites [26] Lu, Y. et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature 588, 124–129 (2020). sourceExperimental — accuracy not yet measured
The “OSK stimulates axon regeneration” section reports axon regeneration in mice. “Axon regeneration in human neurons” reports recovery of axon growth in cultured human neurons, not regeneration demonstrated in human patients. The claim is supported for mice but overextends the human-cell result to humans. (LLM, conf=0.87)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The magnitude of these aggregation and complementarity effects increases with the number of diseases under consideration.”
§ The economic value of targeting aging > Results > Targeting aging versus single diseases
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“If instead we focus on percentage improvements in aging (for example, a 1% slowdown in biological aging rather than a slowdown generating a 1-year increase in LE) then we have increasing WTP at an individual level.”
§ The economic value of targeting aging > Results > Aggregate gains
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This also explains why extending healthspan is eventually preferable to rectangularization.”
§ The economic value of targeting aging > Results > Compressing morbidity (the Dorian Gray case)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
34 more claims
Create a free account to see all 68 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 24
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronological age is the major predictor for most of the diseases that account for the bulk of morbidity, mortality and health costs across low-, middle- and high-income countries2–7.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By understanding and targeting cellular senescence and the other pillars of aging, rather than targeting individual diseases that are downstream of fundamental aging processes, it is conceivable that multimorbidity could be reduced and healthspan increased, with realization of substantial societal and economic benefits4,6.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, modest slowing of the pace of aging can have profound effects on population health11–13.”
From Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial (2023) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The economic value of targeting aging > Results > Life extension (the Struldbrugg case)
“The rectangularization curve shows a survival function in which improvements in LE are achieved through compressing morbidity.”
§ The economic value of targeting aging > Results > Life extension (the Struldbrugg case)
“The result is an expansion of morbidity such that the ratio of HLE to LE deteriorates.”
Citations
Cites
The Epidemiologic Transition: A Theory of the Epidemiology of Population Change
OMRAN, A. R. (2005) · The Milbank Quarterly · doi:10.1111/j.1468-0009.2005.00398.x · Cited by 3,823
Gompertz, B. (1825) · Philosophical Transactions of the Royal Society of London · doi:10.1098/rstl.1825.0026 · Cited by 3,816
Aging, natural death, and the compression of morbidity
Fries, J. F. (1980) · New England Journal of Medicine · doi:10.1056/nejm198007173030304 · Cited by 3,356
Broken Limits to Life Expectancy
Oeppen, J., & Vaupel, J. W. (2002) · Science · doi:10.1126/science.1069675 · Cited by 2,819
Wang, H., Abbas, K. M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., Abolhassani, H., Abreu, L. G., Abrigo, M. R. M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30977-6 · Cited by 1,971
From discoveries in ageing research to therapeutics for healthy ageing
Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., & Verdin, E. (2019) · Nature · doi:10.1038/s41586-019-1365-2 · Cited by 1,389
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
The Fourth Stage of the Epidemiologic Transition: The Age of Delayed Degenerative Diseases
Olshansky, S. J., & Ault, A. B. (1986) · The Milbank Quarterly · doi:10.2307/3350025 · Cited by 820
Reprogramming to recover youthful epigenetic information and restore vision
Lu, Y., Brommer, B., Tian, X., Krishnan, A., Meer, M., Wang, C., Vera, D. L., Zeng, Q., Yu, D., Bonkowski, M. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2975-4 · Cited by 820
Self-citationKirkwood, T. B. L. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0379 · Cited by 608
Research works printed but not linked: 1
- Barzilai, N. Age Later: Health Span, Life Span, and the New Science of Longevity (St Martin’s Press, 2020).
Cited by
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Nandi, A., Counts, N., Chen, S., Seligman, B., Tortorice, D., Vigo, D., & Bloom, D. E. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101580 · Cited by 402
Chen, S., Cao, Z., Nandi, A., Counts, N., Jiao, L., Prettner, K., Kuhn, M., Seligman, B., Tortorice, D., Vigo, D., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00264-x · Cited by 294
Waziry, R., Ryan, C. P., Corcoran, D. L., Huffman, K. M., Kobor, M. S., Kothari, M., Graf, G. H., Kraus, V. B., Kraus, W. E., Lin, D. T. S., et al. (2023) · Nature Aging · doi:10.1038/s43587-022-00357-y · Cited by 217
“Nevertheless, modest slowing of the pace of aging can have profound effects on population health 11–13 .”
Metadata
- Authors
- Scott, A. J., Ellison, M., & Sinclair, D. A.
- Affiliations
- London Business School (GB)
- University of Oxford (GB)
- Harvard University (US)
- Corresponding author
- Scott, Andrew J.
- Venue
- Nature Aging
- Published
- 2021-07-05
- Volume
- 1
- Issue
- 7
- Pages
- 616-623
- ISSN
- 2662-8465 (ISSN-L)
- PMC
- PMC10154220
- OpenAlex
- W3180012192
- Cited by
- 267
- References
- 34
- Citations by year
- 2026: 64 · 2025: 64 · 2024: 59 · 2023: 40 · 2022: 28 · 2021: 12
- FWCI
- 40.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Aging (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- London Business School Research Online (London Business School) (acceptedVersion, cc-by)
- Funders
- RCUK | Economic and Social Research Council (T002204)
- Oxford University | John Fell Fund, University of Oxford
- Glenn Foundation for Medical Research
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Demography › Insurance, Mortality, Demography, Risk Management
- Keywords
- aging, life expectancy, compression of morbidity, healthy aging, anti-aging interventions, disease eradication, health gains, economic valuation of health
- MeSH terms
- Health Status, Life Expectancy, Morbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The economic value of targeting aging. https://app.cochat.ai/papers/10.1038/s43587-021-00080-0
- The paper
- Scott, A. J., Ellison, M., & Sinclair, D. A. (2021). The economic value of targeting aging. Nature Aging. https://doi.org/10.1038/s43587-021-00080-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.